Activation of Toll-Like Receptors and Inflammasome Complexes in the Diabetic Cardiomyopathy-Associated Inflammation

Diabetic cardiomyopathy is defined as a ventricular dysfunction initiated by alterations in cardiac energy substrates in the absence of coronary artery disease and hypertension. Hyperglycemia, hyperlipidemia, and insulin resistance are major inducers of the chronic low-grade inflammatory state that characterizes the diabetic heart. Cardiac Toll-like receptors and inflammasome complexes may be key inducers for inflammation probably through NF-κB activation and ROS overproduction. However, metabolic dysregulated factors such as peroxisome proliferator-activated receptors and sirtuins may serve as therapeutic targets to control this response by mitigating both Toll-like receptors and inflammasome signaling.

[1]  J. Egido,et al.  Eplerenone attenuated cardiac steatosis, apoptosis and diastolic dysfunction in experimental type-II diabetes , 2013, Cardiovascular Diabetology.

[2]  J. Egido,et al.  Alteration of Energy Substrates and ROS Production in Diabetic Cardiomyopathy , 2013, Mediators of inflammation.

[3]  E. Barroso,et al.  An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. , 2013, International journal of cardiology.

[4]  T. Suuronen,et al.  Antagonistic crosstalk between NF-κB and SIRT1 in the regulation of inflammation and metabolic disorders. , 2013, Cellular signalling.

[5]  M. Czech,et al.  Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes , 2013, Nature Medicine.

[6]  M. Mattson,et al.  Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke , 2013, Cell Death and Disease.

[7]  R. Flavell,et al.  Innate sensors of pathogen and stress: linking inflammation to obesity. , 2013, The Journal of allergy and clinical immunology.

[8]  Ting-I Lee,et al.  Peroxisome proliferator-activated receptors modulate cardiac dysfunction in diabetic cardiomyopathy. , 2013, Diabetes research and clinical practice.

[9]  E. Latz,et al.  Activation and regulation of the inflammasomes , 2013, Nature Reviews Immunology.

[10]  M. Gillum,et al.  Sirtuin-1 is a nutrient-dependent modulator of inflammation , 2013, Adipocyte.

[11]  Kan Yang,et al.  Anti-inflammatory effects of triptolide improve left ventricular function in a rat model of diabetic cardiomyopathy , 2013, Cardiovascular Diabetology.

[12]  H. Duff,et al.  The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin‐1β , 2013, Experimental physiology.

[13]  S. Vogel,et al.  Inhibition of TLR4 Signaling by TRAM-Derived Decoy Peptides In Vitro and In Vivo , 2013, The Journal of Immunology.

[14]  C. Thiemermann,et al.  Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR-δ agonism correlates with impaired NLRP3 inflammasome activation. , 2013, Biochemical pharmacology.

[15]  L. Palmqvist,et al.  Reduced expression of NLRP3 and MEFV in human ischemic heart tissue. , 2013, Biochemical and biophysical research communications.

[16]  M. Rossol,et al.  Extracellular Ca2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors , 2012, Nature Communications.

[17]  R. Germain,et al.  The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP , 2012, Nature.

[18]  M. Farkouh,et al.  Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects. , 2012, American heart journal.

[19]  V. Dixit,et al.  Phosphorylation of NLRC4 is critical for inflammasome activation , 2012, Nature.

[20]  Anna K Rieger,et al.  NLRP3 Inflammasome Activity Is Negatively Controlled by miR-223 , 2012, The Journal of Immunology.

[21]  Y. Huang,et al.  TLR4 regulates cardiac lipid accumulation and diabetic heart disease in the nonobese diabetic mouse model of type 1 diabetes. , 2012, American journal of physiology. Heart and circulatory physiology.

[22]  E. Alnemri,et al.  Non-transcriptional Priming and Deubiquitination Regulate NLRP3 Inflammasome Activation* , 2012, The Journal of Biological Chemistry.

[23]  J. Tamargo,et al.  Activation of peroxisome proliferator-activated receptor-β/-δ (PPARβ/δ) prevents endothelial dysfunction in type 1 diabetic rats. , 2012, Free radical biology & medicine.

[24]  C. Zuurbier,et al.  Deletion of the Innate Immune NLRP3 Receptor Abolishes Cardiac Ischemic Preconditioning and Is Associated with Decreased Il-6/STAT3 Signaling , 2012, PloS one.

[25]  M. Lindsey,et al.  Toll-Like Receptor (TLR) 2 and TLR4 Differentially Regulate Doxorubicin Induced Cardiomyopathy in Mice , 2012, PloS one.

[26]  W. Wahli,et al.  PPARs at the crossroads of lipid signaling and inflammation , 2012, Trends in Endocrinology & Metabolism.

[27]  W. Hoffmann,et al.  Variants of Toll-like Receptor 4 Predict Cardiac Recovery in Patients with Dilated Cardiomyopathy* , 2012, The Journal of Biological Chemistry.

[28]  Y. Horio,et al.  Emerging beneficial roles of sirtuins in heart failure , 2012, Basic Research in Cardiology.

[29]  X. Dong,et al.  Sirtuin biology and relevance to diabetes treatment. , 2012, Diabetes management.

[30]  M. Fredrikson,et al.  The Q705K Polymorphism in NLRP3 Is a Gain-of-Function Alteration Leading to Excessive Interleukin-1β and IL-18 Production , 2012, PloS one.

[31]  Jianni Qi,et al.  TLR‐induced NF‐κB activation regulates NLRP3 expression in murine macrophages , 2012, FEBS letters.

[32]  Haitao Wen,et al.  A role for the NLRP3 inflammasome in metabolic diseases—did Warburg miss inflammation? , 2012, Nature Immunology.

[33]  Moshe Arditi,et al.  Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. , 2012, Immunity.

[34]  A. Ortiz,et al.  Proteome changes in the myocardium of experimental chronic diabetes and hypertension: role of PPARα in the associated hypertrophy. , 2012, Journal of proteomics.

[35]  J. Brandão-Neto,et al.  Increased TLR2 expression in patients with type 1 diabetes: evidenced risk of microalbuminuria , 2012, Pediatric diabetes.

[36]  R. Isseroff,et al.  Toll-like receptors and diabetes: a therapeutic perspective. , 2012, Clinical science.

[37]  R. Savani,et al.  Toll-like receptors, the NLRP3 inflammasome, and interleukin-1β in the development and progression of type 1 diabetes , 2012, Pediatric Research.

[38]  A. Rosenzweig,et al.  The fire within: cardiac inflammatory signaling in health and disease. , 2012, Circulation research.

[39]  Ying He,et al.  Sirtuin 1–Mediated Cellular Metabolic Memory of High Glucose Via the LKB1/AMPK/ROS Pathway and Therapeutic Effects of Metformin , 2011, Diabetes.

[40]  T. Peng,et al.  MicroRNA-195 promotes palmitate-induced apoptosis in cardiomyocytes by down-regulating Sirt1. , 2011, Cardiovascular research.

[41]  F. Pashkow Oxidative Stress and Inflammation in Heart Disease: Do Antioxidants Have a Role in Treatment and/or Prevention? , 2011, International journal of inflammation.

[42]  M. Lopes-Virella,et al.  DPP-4 (CD26) Inhibitor Alogliptin Inhibits Atherosclerosis in Diabetic Apolipoprotein E–Deficient Mice , 2011, Journal of cardiovascular pharmacology.

[43]  P. Knuefermann,et al.  The toll‐like receptor 4‐antagonist eritoran reduces murine cardiac hypertrophy , 2011, European journal of heart failure.

[44]  J. Egido,et al.  Potential Role of Nuclear Factor κB in Diabetic Cardiomyopathy , 2011, Mediators of inflammation.

[45]  Denis Gris,et al.  Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signaling , 2011, Nature Immunology.

[46]  F. Pattou,et al.  PPARβ/δ activation induces enteroendocrine L cell GLP-1 production. , 2011, Gastroenterology.

[47]  A. Choi,et al.  Dampening insulin signaling by an NLRP3 'meta-flammasome' , 2011, Nature Immunology.

[48]  F. Villarroya,et al.  Sirt1 acts in association with PPARα to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. , 2011, Cardiovascular research.

[49]  P. Elliott,et al.  Meta-Analysis of Genome-Wide Association Studies in >80 000 Subjects Identifies Multiple Loci for C-Reactive Protein Levels , 2011, Circulation.

[50]  T. Noda,et al.  Inflammasome Activation of Cardiac Fibroblasts Is Essential for Myocardial Ischemia/Reperfusion Injury , 2011, Circulation.

[51]  W. Wahli,et al.  PPARβ/δ activation blocks lipid-induced inflammatory pathways in mouse heart and human cardiac cells. , 2011, Biochimica et biophysica acta.

[52]  D. Charnock-Jones,et al.  Developmental control of the Nlrp6 inflammasome and a substrate, IL-18, in mammalian intestine. , 2011, American journal of physiology. Gastrointestinal and liver physiology.

[53]  Z. Shan,et al.  Hyperglycemic Myocardial Damage Is Mediated by Proinflammatory Cytokine: Macrophage Migration Inhibitory Factor , 2011, PloS one.

[54]  C. McCall,et al.  NAD+-dependent SIRT1 Deacetylase Participates in Epigenetic Reprogramming during Endotoxin Tolerance* , 2011, The Journal of Biological Chemistry.

[55]  N. Tsuchimori,et al.  TAK-242 (Resatorvid), a Small-Molecule Inhibitor of Toll-Like Receptor (TLR) 4 Signaling, Binds Selectively to TLR4 and Interferes with Interactions between TLR4 and Its Adaptor Molecules , 2011, Molecular Pharmacology.

[56]  S. Prabhu,et al.  Cardiomyocyte NF-κB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. , 2011, Cardiovascular research.

[57]  Xiaoshu Cheng,et al.  Prevention of hyperglycemia-induced myocardial apoptosis by gene silencing of Toll-like receptor-4 , 2010, Journal of Translational Medicine.

[58]  M. McDermott,et al.  Gevokizumab, an anti-IL-1β mAb for the potential treatment of type 1 and 2 diabetes, rheumatoid arthritis and cardiovascular disease. , 2010, Current opinion in molecular therapeutics.

[59]  L. Joosten,et al.  The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. , 2010, Cell metabolism.

[60]  C. Glass,et al.  ATVB in Focus Nuclear Receptors in Metabolism and Cardiovascular Disease , 2010 .

[61]  L. O’Neill,et al.  New Insights into the Regulation of Signalling by Toll-Like Receptors and Nod-Like Receptors , 2010, Journal of Innate Immunity.

[62]  J. Kieswich,et al.  Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. , 2010, The Journal of endocrinology.

[63]  J. Olefsky,et al.  SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity. , 2010, American journal of physiology. Endocrinology and metabolism.

[64]  J. Tschopp,et al.  Thioredoxin-interacting protein links oxidative stress to inflammasome activation , 2010, Nature Immunology.

[65]  Kate Schroder,et al.  The NLRP3 Inflammasome: A Sensor for Metabolic Danger? , 2010, Science.

[66]  S. Devaraj,et al.  Increased Toll-Like Receptor (TLR) Activation and TLR Ligands in Recently Diagnosed Type 2 Diabetic Subjects , 2010, Diabetes Care.

[67]  P. Doevendans,et al.  Myocardial Ischemia / Reperfusion Injury Is Mediated by Leukocytic Toll-Like Receptor-2 and Reduced by Systemic Administration of a Novel Anti – Toll-Like Receptor-2 Antibody , 2009 .

[68]  A. Sanz,et al.  Myocardial fibrosis and apoptosis, but not inflammation, are present in long-term experimental diabetes. , 2009, American journal of physiology. Heart and circulatory physiology.

[69]  V. Dixit,et al.  Glyburide inhibits the Cryopyrin/Nalp3 inflammasome , 2009, The Journal of cell biology.

[70]  M. Fessler,et al.  Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome , 2009, Current opinion in lipidology.

[71]  M. Holness,et al.  The role of PPARs in modulating cardiac metabolism in diabetes. , 2009, Pharmacological research.

[72]  K. E. Jones,et al.  Nutrient Stress Activates Inflammation and Reduces Glucose Metabolism by Suppressing AMP-Activated Protein Kinase in the Heart , 2009, Diabetes.

[73]  T. Matsuo,et al.  Roles of TLR2, TLR4, NOD2, and NOD1 in Pulp Fibroblasts , 2009, Journal of dental research.

[74]  S. Devaraj,et al.  Pioglitazone inhibits Toll-like receptor expression and activity in human monocytes and db/db mice. , 2009, Endocrinology.

[75]  I. Karakikes,et al.  Gene Remodeling in Type 2 Diabetic Cardiomyopathy and Its Phenotypic Rescue with SERCA2a , 2009, PloS one.

[76]  E. Alnemri,et al.  Cutting Edge: NF-κB Activating Pattern Recognition and Cytokine Receptors License NLRP3 Inflammasome Activation by Regulating NLRP3 Expression1 , 2009, The Journal of Immunology.

[77]  Jie Huang,et al.  The IκBα gene is a peroxisome proliferator‐activated receptor cardiac target gene , 2009, The FEBS journal.

[78]  R. Cooksey,et al.  Mechanisms for increased myocardial fatty acid utilization following short-term high-fat feeding. , 2009, Cardiovascular research.

[79]  Hong Jiang,et al.  Valsartan preconditioning protects against myocardial ischemia–reperfusion injury through TLR4/NF-κB signaling pathway , 2009, Molecular and Cellular Biochemistry.

[80]  P. Sritara,et al.  Atorvastatin attenuates TLR4-mediated NF-kappaB activation in a MyD88-dependent pathway. , 2009, Asian Pacific journal of allergy and immunology.

[81]  C. Buechler,et al.  Fatty acid‐induced induction of Toll‐like receptor‐4/nuclear factor‐κB pathway in adipocytes links nutritional signalling with innate immunity , 2009, Immunology.

[82]  C. Zhang,et al.  Effects and mechanisms of PPARα activator fenofibrate on myocardial remodelling in hypertension , 2008, Journal of cellular and molecular medicine.

[83]  T. Chan,et al.  TNF- a reduces PGC-1 a expression through NF- k B and p38 MAPK leading to increased glucose oxidation in a human cardiac cell model , 2009 .

[84]  D. White,et al.  MOLECULAR OR PHARMACOLOGIC INHIBITION OF THE CD14 SIGNALING PATHWAY PROTECTS AGAINST BURN-RELATED MYOCARDIAL INFLAMMATION AND DYSFUNCTION , 2008, Shock.

[85]  W. Wahli,et al.  Activation of Peroxisome Proliferator–Activated Receptor β/δ Inhibits Lipopolysaccharide-Induced Cytokine Production in Adipocytes by Lowering Nuclear Factor-κB Activity via Extracellular Signal–Related Kinase 1/2 , 2008, Diabetes.

[86]  P. Pfluger,et al.  Sirt1 protects against high-fat diet-induced metabolic damage , 2008, Proceedings of the National Academy of Sciences.

[87]  R. DeFronzo,et al.  Elevated Toll-Like Receptor 4 Expression and Signaling in Muscle From Insulin-Resistant Subjects , 2008, Diabetes.

[88]  G. Ertl,et al.  Toll-like receptor signaling in the ischemic heart. , 2008, Frontiers in bioscience : a journal and virtual library.

[89]  Toshiyuki Takahashi Toll-like receptors and myocardial contractile dysfunction. , 2008, Cardiovascular research.

[90]  P. Söderkvist,et al.  Gene polymorphisms in the NALP3 inflammasome are associated with interleukin-1 production and severe inflammation: relation to common inflammatory diseases? , 2008, Arthritis and rheumatism.

[91]  P. Poole‐Wilson,et al.  Fluvastatin reduces increased blood monocyte Toll-like receptor 4 expression in whole blood from patients with chronic heart failure. , 2008, International journal of cardiology.

[92]  Xianlin Han,et al.  Nuclear receptors PPARβ/δ and PPARα direct distinct metabolic regulatory programs in the mouse heart , 2007 .

[93]  M. Racke,et al.  Peroxisome proliferator‐activated receptor‐α agonist fenofibrate regulates IL‐12 family cytokine expression in the CNS: relevance to multiple sclerosis , 2007, Journal of neurochemistry.

[94]  Amy V. Lynch,et al.  Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes , 2007, Nature.

[95]  J. Plutzky,et al.  PPARα in atherosclerosis and inflammation , 2007 .

[96]  S. Malozowski,et al.  Interleukin-1-receptor antagonist in type 2 diabetes mellitus. , 2007, The New England journal of medicine.

[97]  C. Tschöpe,et al.  Cardioprotective and Anti-Inflammatory Effects of Interleukin Converting Enzyme Inhibition in Experimental Diabetic Cardiomyopathy , 2007, Diabetes.

[98]  E. Abel,et al.  Diabetic cardiomyopathy revisited. , 2007, Circulation.

[99]  S. Vatner,et al.  Sirt1 Regulates Aging and Resistance to Oxidative Stress in the Heart , 2007, Circulation research.

[100]  F. Martinon,et al.  Inflammasome Components NALP 1 and 3 Show Distinct but Separate Expression Profiles in Human Tissues Suggesting a Site-specific Role in the Inflammatory Response , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[101]  R. Caprioli,et al.  Alterations in the diabetic myocardial proteome coupled with increased myocardial oxidative stress underlies diabetic cardiomyopathy. , 2007, Journal of molecular and cellular cardiology.

[102]  M. Lohse,et al.  A Role for Caspase-1 in Heart Failure , 2007, Circulation research.

[103]  S. Anker,et al.  Contributions of Inflammation and Cardiac Matrix Metalloproteinase Activity to Cardiac Failure in Diabetic Cardiomyopathy , 2007, Diabetes.

[104]  L. Gan,et al.  Parallel gene expressions of IL-6 and BNP during cardiac hypertrophy complicated with diastolic dysfunction in spontaneously hypertensive rats. , 2007, International journal of cardiology.

[105]  K. Walley,et al.  Toll-like receptor stimulation in cardiomyoctes decreases contractility and initiates an NF-kappaB dependent inflammatory response. , 2006, Cardiovascular research.

[106]  J. Flier,et al.  TLR4 links innate immunity and fatty acid-induced insulin resistance. , 2006, The Journal of clinical investigation.

[107]  E. Verrier,et al.  Inhibition of Toll-like Receptor 4 With Eritoran Attenuates Myocardial Ischemia-Reperfusion Injury , 2006, Circulation.

[108]  H. Grafenstein,et al.  Dysregulated Toll-like receptor expression and signaling in bone marrow-derived macrophages at the onset of diabetes in the non-obese diabetic mouse. , 2006, International immunology.

[109]  I. Komuro,et al.  [Molecular mechanisms of congestive heart failure]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[110]  S. Akira,et al.  TLR signaling. , 2006, Current topics in microbiology and immunology.

[111]  R. DePinho,et al.  The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin , 2005, Science.

[112]  H. Methe,et al.  Expansion of Circulating Toll-Like Receptor 4–Positive Monocytes in Patients With Acute Coronary Syndrome , 2005, Circulation.

[113]  B. Horne,et al.  Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. , 2004, American heart journal.

[114]  W. Wahli,et al.  PPARs as drug targets to modulate inflammatory responses? , 2004, Current drug targets. Inflammation and allergy.

[115]  M. Tsan,et al.  Endogenous ligands of Toll‐like receptors , 2004, Journal of leukocyte biology.

[116]  Thomas H Marwick,et al.  Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. , 2004, Endocrine reviews.

[117]  M. Mayo,et al.  Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase , 2004, The EMBO journal.

[118]  Douglas L Mann,et al.  Inflammatory mediators and the failing heart: past, present, and the foreseeable future. , 2002, Circulation research.

[119]  H. Taegtmeyer,et al.  Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. , 2002, Circulation.

[120]  S. Frantz,et al.  Role of TLR-2 in the Activation of Nuclear Factor κB by Oxidative Stress in Cardiac Myocytes* , 2001, The Journal of Biological Chemistry.

[121]  W. Kannel,et al.  Role of diabetes in congestive heart failure: the Framingham study. , 1974, The American journal of cardiology.

[122]  A. Grishman,et al.  New type of cardiomyopathy associated with diabetic glomerulosclerosis. , 1972, The American journal of cardiology.